G1 Therapeutics, Inc. Banner Image

G1 Therapeutics, Inc.

  • Ticker GTHX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
G1 Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Research Triangle Park, North Carolina
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrantMore is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
4.7 / 5.0 (132)

G1 Therapeutics, Inc. reports have an aggregate usefulness score of 4.7 based on 132 reviews.

G1 Therapeutics, Inc.

Most Recent Annual Report

G1 Therapeutics, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

G1 Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!